Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,187,568
  • Shares Outstanding, K 5,662,542
  • Annual Sales, $ 58,496 M
  • Annual Income, $ 2,119 M
  • 60-Month Beta 0.61
  • Price/Sales 2.46
  • Price/Cash Flow 8.49
  • Price/Book 1.60
Trade PFE with:

Options Overview Details

View History
  • Implied Volatility 31.74% ( +3.00%)
  • Historical Volatility 18.01%
  • IV Percentile 94%
  • IV Rank 86.99%
  • IV High 33.73% on 10/27/23
  • IV Low 18.44% on 06/09/23
  • Put/Call Vol Ratio 0.47
  • Today's Volume 210,102
  • Volume Avg (30-Day) 153,314
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 3,207,160
  • Open Int (30-Day) 3,075,769

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.56
  • Number of Estimates 8
  • High Estimate 0.82
  • Low Estimate 0.40
  • Prior Year 1.23
  • Growth Rate Est. (year over year) -54.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.20 +1.67%
on 04/26/24
27.87 -8.07%
on 04/01/24
-2.13 (-7.68%)
since 03/28/24
3-Month
25.20 +1.67%
on 04/26/24
28.69 -10.70%
on 03/13/24
-1.40 (-5.18%)
since 01/30/24
52-Week
25.20 +1.67%
on 04/26/24
40.37 -36.53%
on 06/13/23
-13.27 (-34.12%)
since 04/28/23

Most Recent Stories

More News
Pfizer and Genmab Receive FDA Approval for Cervical Cancer Drug

In late April, Pfizer (NYSE:PFE) and Genmab received approval from the United States Food and Drug Administration ...

PFE : 25.62 (-0.08%)
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...

ONCY : 1.1100 (+1.83%)
ICCM : 1.1900 (-0.83%)
ATOS : 1.5100 (-1.31%)
ARVN : 31.77 (-0.41%)
PFE : 25.62 (-0.08%)
ONC.TO : 1.53 (+2.00%)
Biotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming Rate

USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is...

ONCY : 1.1100 (+1.83%)
ONC.TO : 1.53 (+2.00%)
ICCM : 1.1900 (-0.83%)
ATOS : 1.5100 (-1.31%)
ARVN : 31.77 (-0.41%)
PFE : 25.62 (-0.08%)
5 Top Stocks to Buy in May

Whether you're looking for a proven player, passive income, or a breakout growth story, there are plenty of stocks worth buying this spring.

MSFT : 389.33 (-3.21%)
PFE : 25.62 (-0.08%)
NEE : 66.97 (-0.67%)
HD : 334.22 (-0.77%)
FVRR : 20.51 (-2.84%)
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist

The sun could be peeking through the dark clouds for Pfizer.

PFE : 25.62 (-0.08%)
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead

Wall Street's brightest, most successful billionaire money managers are ditching Nvidia in favor of two time-tested income stocks with yields of 6.6%!

NVDA : 864.02 (-1.54%)
T : 16.89 (-0.76%)
PFE : 25.62 (-0.08%)
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole

These stocks aren't bargains.

MRNA : 110.31 (-1.17%)
PFE : 25.62 (-0.08%)
NVAX : 4.33 (+0.93%)
CHGG : 5.17 (-27.89%)
ACB : 9.23 (+46.04%)
Stocks Set to Open Higher as Investors Await U.S. Jobs Data and More Big Tech Earnings, Fed Meeting on Tap

June S&P 500 E-Mini futures (ESM24) are up +0.19%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.28% this morning as investors looked ahead to earnings reports from some of the world’s most prominent...

ESM24 : 5,058.25 (-0.17%)
NQM24 : 17,510.00 (-0.35%)
GOOGL : 162.78 (-2.03%)
RMD : 213.99 (-1.47%)
MSFT : 389.33 (-3.21%)
INTC : 30.47 (-2.84%)
AAPL : 170.33 (-1.83%)
AMZN : 175.00 (-3.29%)
AMD : 158.38 (-1.14%)
QCOM : 165.85 (-1.98%)
KO : 61.77 (-0.44%)
MCD : 273.04 (-0.19%)
Is Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

PFE : 25.62 (-0.08%)
VKTX : 79.58 (+5.52%)
LLY : 781.10 (+5.95%)
NVO : 128.31 (+1.13%)
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

BAM : 38.19 (-4.41%)
PFE : 25.62 (-0.08%)
BIP : 26.87 (-0.78%)
BIPC : 30.47 (-2.21%)
BEP : 21.01 (-1.73%)
BEPC : 23.24 (-1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.02
2nd Resistance Point 25.93
1st Resistance Point 25.77
Last Price 25.62
1st Support Level 25.52
2nd Support Level 25.43
3rd Support Level 25.27

See More

52-Week High 40.37
Fibonacci 61.8% 34.57
Fibonacci 50% 32.78
Fibonacci 38.2% 30.99
Last Price 25.62
52-Week Low 25.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar